A Johnson & Johnson executive sold half her stake, totaling $5.8 million, amid a 27% year-to-date stock gain.
Johnson & Johnson’s EVP of Global Corporate Affairs, Vanessa Broadhurst, sold 23,054 shares worth approximately $5.8 million on July 20. The sale represents about 50% of her holdings in the company, which has seen its stock rise 27% year-to-date.
The company has undergone significant restructuring, including the 2023 spin-off of its consumer health unit and the separation of its orthopedics business. Management projects 6% operational sales growth for 2026, targeting double-digit revenue growth by the decade’s end, supported by a robust pharma pipeline and $20 billion in annual free cash flow.
Analysts suggest the insider sale reflects profit-taking rather than concerns, though the move contrasts with President Trump’s disclosed holdings in JNJ earlier this year.